ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

PEG-hGH Injection

Its studies are led by Changchun GeneScience Pharmaceutical.

Furthest: phase 3, since Sep 20, 20261 company-led study, 1 open or runningNext primary completion: Sep 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Changchun GeneScience Pharmaceutical11 open or runningphase 3since Sep 20, 2026Sep 20, 2026Sep 2028phase 3 · NCT07841678

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 20, 2026First study: phase 3 study in Small for Gestational AgeFirst studyNCT07841678 · 105 planned · China

Ahead

  1. Sep 2028Primary completion: phase 3 study in Small for Gestational AgeNCT07841678

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07841678Small for Gestational Age · China3Not yet recruitingSep 2028105

How it is read

Names in the registry

  • “PEG-hGH Injection”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.